Case Report

Cyproheptadine adverse drug interaction with anti-epileptic drugs

Ankit Bhardwaj*, Anand Shukla, Sunita Singh, Anil Kem

INTRODUCTION

Histamine is found to take part in the inhibition of seizures via H1 and 5- HT1/2 histamine receptors. In past epileptic patients were frequently prescribed cyproheptadine, as an appetite stimulant for the treatment of anorexia associated with anti-epileptic drugs and for the management of ‘serotonin syndrome’ in depressed epileptic patients. Cyproheptadine antagonizing subtypes of 5- HT1/2 receptors and H1 receptor and decreases neurotransmission of serotonin, which in turn reduces seizures threshold.

If used chronically it is found to increase the severity of seizure and decreases efficacy of antiepileptic drugs in animal study.¹

CASE REPORT

A 13 years old male, resident of Khajuri, Delhi, presented to us with history of multiple episodes of General clonic tonic seizures from last 3 days. Patients is known case of sub-acute sclerosing pan encephalitis stage III with quadriplegia and seizure disorder. Old MRI imaging suggestive of T1/T2 prolongation and mild restricted diffusion seen in bilateral basal ganglia region, suggestive of gliosis/metabolic etiology. The patient was conscious at the time of hospital visit. At admission at our health care facility, child was sick looking and mild pallor. On Primary survey: Airway: Patent.

Bilateral chest rises present, bilateral air entry equal, respiratory rate of 22/min, SPO2: 98% on room air. GCS-

© the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
E4V2M6, pupils 2mm BERL, moving all four limb, no external injuries noted. ECG was with in normal range.

Peripheries were cold and peripheral pulses well felt. CRT less than 2sec. HR-96/min, BP- 114/86mm Hg. Inj. Levetiracetam 1.35gm given IV bolus. Blood sample collected. Investigations revealed anemia (Hb 9g/dL), (TLC: 9.9 × 109/L), Normal liver and renal function tests. Blood culture and Widal test were negative. Urine routine and microscopy was normal. RBS random 134mg/dl. Sr. Calcium 8.8mg/dl and sr. magnesium 1.6meq/l. MRI brain: showed symmetric area of prolongation and mild restricted diffusion seen in bilateral basal ganglia region suggestive of gliosis of metabolic etiology.

DISCUSSION

Cyproheptadine is a H1 receptor and 5-HT1/2 antagonist. The study of serotonergic and histaminergic pathway shows that the decreased neurotransmission of serotonin and histamine in the brain reduces seizures threshold. Since, cyproheptadine interferes with these pathways via antagonizing subtypes of H1 and 5-HT1/2 receptors, impairing the anticonvulsant activity of some antiepileptic drugs and reduces threshold, increases severity of seizures and decreases the efficacy of clinically used antiepileptic drugs, especially when administered chronically. Example of antiepileptic drugs who activities impaired by H1 and 5-HT1/2 receptor antagonist are phenobarbital, phenytoin, valproic acid and devaloprex sodium in maximal electroshock induced convulsions in mice. Few days back he started taking Syp. Cyproheptadine over the counter for increasing his appetite. Later he had 2 episodes of convulsions. He was kept under observation for 3 days. Syp Cyproheptadine was stopped. MRI brain showed symmetric area of prolongation and mild restricted diffusion seen in bilateral basal ganglia region suggestive of gliomas of metabolic etiology. Blood, CSF and urine culture showed no growth. CSF analysis showed positive IgG for measles. All other cause of seizure was ruled out. After stopping cyproheptadine, patient didn’t sustain any further seizures. Later patent was discharged on same epileptic drugs.

CONCLUSION

Cyproheptadine can cause seizures in epileptic and in non-epileptic patient. Cyproheptadine reduces threshold, increases severity of seizures and decreases the efficacy of clinically used anti-epileptic drugs.

ACKNOWLEDGEMENTS

Authors would like to thank Dr. Niraj Jain, Dr. Alok Pandey, for his support during study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
